Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor announced a webcast on Monday, October 26 at 7:00 a.m. EDT to discuss Phase 1 results for XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody in development for advanced clear cell renal cell carcinoma. The data will be presented October 25 in an oral presentation at the ESMO Congress 2026 in Madrid, covering intravenous doses being evaluated for recommended Phase 3 dose selection.
Key figures
- Drug Name
- XmAb819 (ENPP3 x CD3 bispecific antibody)
- Phase Of Trial
- Phase 1
- Nct id
- NCT05433142
- Webcast date
- 2026-10-26
- Phase3 study start
- 2027
- Esmo presentation date
- 2026-10-25
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.